Related Experiment Videos
Frequency of attendance at anticoagulant clinics
Insights
Long-term anticoagulant therapy patients with excellent control can be safely monitored every 3 months. This extended interval for select patients receiving anticoagulation treatment offers significant cost savings.
Area of Science:
- Cardiology
- Pharmacology
- Health Services Research
Background:
- Clinic attendance frequency for long-term anticoagulant patients varies significantly across healthcare centers.
- Current recommendations suggest shorter intervals than the 3-month monitoring policy at this hospital for patients with good anticoagulant control.
Purpose of the Study:
- To assess the safety and efficacy of a 3-month clinic attendance interval for long-term anticoagulant patients with a history of good anticoagulant control.
- To identify a subgroup of patients suitable for extended monitoring intervals.
- To evaluate the potential cost implications of adjusting monitoring frequency.
Main Methods:
- Retrospective analysis of 461 long-term anticoagulant patients' clinic visit data over one year.
- Examination of anticoagulant control, specifically the British ratio, for patients seen at 3-month intervals.
- Categorization of patients based on visit frequency over the last 5 visits.
Main Results:
- 46% of patients were monitored exclusively at 3-month intervals over the last 5 visits.
- These patients demonstrated excellent anticoagulant control, with 88% of visits falling within the British ratio range of 2.0-4.0.
- The findings suggest a potential for safe extended monitoring in a subset of patients.
Conclusions:
- A significant subgroup of chronic anticoagulant patients with excellent control can be safely monitored every 3 months.
- Implementing 3-month monitoring for this subgroup has considerable cost-saving implications for healthcare services.
- This study supports personalized monitoring strategies in long-term anticoagulation management.
Abstract:
The frequency of clinic attendance of long-term anticoagulant patients varies considerably between centres. At this hospital, patients with a record of good anticoagulant control are seen every 3 months, which is double the currently recommended period. To assess this policy, the British ratio of 461 patients on long-term anticoagulants was examined at each visit over the last year. 46% of patients had been seen only at 3-month intervals over the last 5 visits and their anticoagulant control was excellent, 88% of visits falling in the British ratio range 2.0-4.0. It is concluded that amongst chronic anticoagulant patients a significant subgroup may be identified who can safely be monitored at 3-monthly intervals, and this has considerable cost implications.